Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study Evaluating the Efficacy and Safety of Fenofibrates Versus Silymarin in Adult Patients With Sepsis
Sponsor: Tanta University
Summary
Sepsis is a life-threatening condition defined by organ dysfunction resulting from the body's dysregulated response to an infection (1). It begins with widespread inflammation and cellular damage, which quickly escalates into total circulatory failure and the breakdown of essential organ systems, including the lungs, kidneys, digestive tract, and brain. This study aims at evaluating the safety and efficacy of fenofibrate versus silymarin for adult patients with sepsis.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
66
Start Date
2026-05
Completion Date
2028-04
Last Updated
2026-05-07
Healthy Volunteers
No
Conditions
Interventions
Fenofibrate
fenofibrate (145 mg) once daily plus conventional sepsis therapy for 7 days.
Silymarin
silymarin does ranged between (980 - 1120 mg) daily, in divided doses plus conventional sepsis therapy for 7 days.